Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) fell in after-market trading after the company reported Q1 results.
Quarterly Results
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Earnings per share rose 16.41% over the past year to $2.98, which beat the estimate of $2.69.
Revenue of $1,724,000,000 rose by 13.80% year over year, which beat the estimate of $1,660,000,000.
Looking Ahead
Vertex Pharmaceuticals hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Date: Apr 29, 2021
Time: 05:30 PM
ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1451777&tp_key=70be10c00f
Price Action
52-week high: $306.08
Company's 52-week low was at $202.56
Price action over last quarter: down 2.52%
Company Description
Vertex Pharmaceuticals Inc discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. The company's pipeline also includes genetic therapies like CTX001 for beta-thalassemia and sickle-cell disease as well as small-molecule medicines targeting diseases associated with alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease. In addition, Vertex is focusing on developing therapies for pain, type 1 diabetes, inflammatory diseases, influenza, and other rare diseases.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.